The authors concluded that use of injected insulin predisposes to inflammation, atherosclerosis, hypertension, dyslipidemia, heart failure, and arrhythmias, showing that insulin therapy has an overall poorer safety profile than that found with several other therapies used to treat T2D. The gene discussed is INS; the disease is atherosclerosis.